AChE inhibitors form one of the most actively investigated classes of compounds having been labeled as a potential agent for the treatment of AD by inhibiting AChE from hydrolyzing ACh, thereby leading to increases in the level of ACh (Birks, 2006). This evidence concerns the gene ACHE and Alzheimer disease.